Assess whether scientific advice should be sought before the next trial

Situation

The Pharmacovigilance desk packet is CMC comparability package for a site change after an FAERS cluster in a demographic the trials under-enrolled. Pharmacovigilance medical reviewer in a labeling team facing a boxed-warning debate must name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences file. Pharmacovigilance medical reviewer in a labeling team facing a boxed-warning debate has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences Pharmacovigilance file.

Decision

Pharmacovigilance medical reviewer in a labeling team facing a boxed-warning debate must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using CMC comparability package for a site change after an FAERS cluster in a demographic the trials under-enrolled.

Hypotheses to test

• Pharmacovigilance medical reviewer can defend Proceed under protocol from CMC comparability package for a site change after an FAERS cluster in a demographic the trials under-enrolled in a Pharma & Life Sciences challenge.
• Pharmacovigilance medical reviewer cannot defend Proceed under protocol from CMC comparability package for a site change; Pause the pathway is what the extract actually supports after an FAERS cluster in a demographic the trials under-enrolled.
• An FAERS cluster in a demographic the trials under-enrolled never reached the population in CMC comparability package for a site change — reopen intake, do not close scientific advice should be.
• Two facts in CMC comparability package for a site change after an FAERS cluster in a demographic the trials under-enrolled conflict for pharmacovigilance medical reviewer; hold this Pharmacovigilance file.

Analysis required

• Check whether CMC comparability package for a site change supports the labeled claim pharmacovigilance medical reviewer would keep.
• Map FDA-response timing and owner in a labeling team facing a boxed-warning debate.
• Trace CMC, labeling, or pharmacovigilance facts in CMC comparability package for a site change after an FAERS cluster in a demographic the trials under-enrolled.
• For this Pharma & Life Sciences Pharmacovigilance file, read CMC comparability package for a site change against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move scientific advice should be for pharmacovigilance medical reviewer.